Polyphor shareholders approve all motions proposed by the Board of Directors at the Annual General Meeting Freitag, 12. April 2019 - 17:45

Polyphor AG / Key word(s): AGMEGM
Polyphor shareholders approve all motions proposed by the Board of Directors
at the Annual General Meeting

12.04.2019 / 17:45

---------------------------------------------------------------------------

Allschwil, Switzerland, April 12, 2019


Polyphor shareholders approve all motions proposed by the Board of Directors
at the Annual General Meeting


Polyphor AG (SIX: POLN) shareholders today approved all motions put forward
by the Board of Directors to the 22nd Annual General Meeting in Basel. The
meeting was attended by 62 shareholders. A total of 50% of the company's
voting share capital was represented.

The members of the Board of Directors, Argeris N. Karabelas, Kuno Sommer,
Bernard Bollag, Silvio Inderbitzin, Jean-Pierre Obrecht, Andreas Wallnöfer
and Frank T. Weber were re-elected for a further year in office. In
addition, the shareholders approved the re-election of Argeris N. Karabelas
as Chairman of the Board of Directors.

The shareholders also approved the total maximum amount of compensation for
the Board of Directors and the total maximum amount of compensation for the
members of the Executive Management for the financial year 2019.
Furthermore, shareholders also approved the increase of conditional capital
for employee benefit plans.


For further information please contact:

For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com


For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch

About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the
discovery and development of antibiotics and immuno-oncology compounds. It
has discovered and is developing the OMPTA (Outer Membrane Protein Targeting
Antibiotics). The OMPTA are potentially the first new class of antibiotics
against Gram-negative bacteria to have reached phase III stage in the last
50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III
development against Pseudomonas aeruginosa - recognized as a critical
priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline
of further preclinical antibiotics based on its OMPTA platform. In addition,
Polyphor is developing an immuno-oncology candidate, balixafortide
(POL6326), which is starting a Phase III trial in combination with eribulin
in patients with advanced breast cancer, and exploring in parallel its
potential for further combinations and indications. Polyphor is based in
Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).
For more information, please visit www.polyphor.com.


Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of the Polyphor management. Known and
unknown risks, uncertainties, and other factors could lead to material
differences between the forward-looking statements made here and the actual
development, in particular Polyphor's results, financial situation, and
performance. Readers are cautioned not to put undue reliance on
forward-looking statements, which speak only of the date of this
communication. Polyphor disclaims any intention or obligation to update and
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.